Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 8/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 4/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.34 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5593910 | 0.81 | HSD17B10 (0.51) | KAT2BCYP3A4FEN1HSD17B10MAP4K4 | |
| SCHEMBL5593769 | 0.78 | NOTUM (0.50) | KAT2BCYP3A4DRD4DRD2DRD3 | |
| SCHEMBL678175 | 0.77 | KAT2B (0.58) | KAT2B | |
| SCHEMBL5593712 | 0.71 | KAT2B (0.55) | KAT2BHSD17B10ALDH1A1 | |
| SCHEMBL80967 | 0.71 | KAT2B (0.58) | KAT2BHSD17B10ALDH1A1 | |
| SCHEMBL11493879 | 0.70 | QPCT (0.49) | CYP3A4HSD17B10MAP4K4DRD4DRD2 | |
| Hydrochloric Acid SCHEMBL9517520 | 0.70 | KAT2B (0.56) | KAT2BHSD17B10ALDH1A1 | |
| SCHEMBL3655957 | 0.69 | ALDH1A1 (0.57) | KAT2BCYP3A4HSD17B10ALDH1A1 | |
| SCHEMBL11488816 | 0.68 | CYP3A4 (0.38) | CYP3A4HSD17B10MAP4K4DRD4HTR2C | |
| SCHEMBL14640440 | 0.68 | KAT2B (0.50) | KAT2BHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001932-A2 | SUBSTITUTED ISOTHIAZOLONES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001932-A2 | SUBSTITUTED ISOTHIAZOLONES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293374-A1 | Substituted isothiazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293374-A1 | Substituted isothiazolones | LTB4R2, PTGES2, CYSLTR2 | KAT2B 1199/4885CYP3A4 919/4885FEN1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.